Malaria Vaccine: Pfs230

疟疾疫苗：Pfs230

• 批准号: 8745458
• 负责人: Patrick Duffy
• 金额: $ 168.11万
• 依托单位: NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/8745458
• 关键词: Animals; Antibodies; Area; Biological Assay; Complement; Cyclic GMP; Data; Escherichia coli; Germ; Goals; Human; Immune Sera; Malaria; Malaria Vaccines; Membrane; Parasites; Pichia; Population; Production; Proteins; Recombinants; Surface; Vaccines; Wheat; base; burden of illness; expression cloning; feeding; success; transmission process; vaccine evaluation

Built on success in evaluating the wheat germ-expressed Pfs230 domains, recombinant Pfs230 domains were also expressed in P. pastoris and E. coli. Antisera raised against these domains demonstrated potent transmission blocking activities in an ex vivo standard membrane feeding assay, in a complement-dependent manner. Multiple expression clones were evaluated for their recombinant Pfs230 production yield and induction of functional antibodies. A Pichia expression clone was selected, and cGMP grade recombinant Pfs230 was manufactured. The current efforts are focused on generating cGMP grade Pfs230-EPA, to be combined with Pfs25-EPA vaccine and tested in humans as potentially effective transmission blocking vaccine.

在成功评估小麦胚表达Pfs 230结构域的基础上，重组Pfs 230结构域也在巴斯德毕赤酵母和E.杆菌 针对这些结构域产生的抗血清在离体标准膜饲养试验中以补体依赖性方式表现出强效的传播阻断活性。 评价多个表达克隆的重组Pfs 230产率和功能性抗体的诱导。 选择毕赤酵母表达克隆，并制备cGMP级重组Pfs 230。 目前的努力集中在产生cGMP级Pfs 230-EPA，与Pfs 25-EPA疫苗组合并在人体中测试为潜在有效的传播阻断疫苗。